Medicare coverage for Invega Sustenna (paliperidone palmitate) depends on several factors, including the specific Medicare plan and the reason for its prescription.
How does Medicare decide if it covers Invega Sustenna?
Medicare coverage for medications like Invega Sustenna typically falls under Medicare Part D, the prescription drug benefit. Coverage decisions are based on whether the drug is considered medically necessary for the patient's condition and if it is included on the plan's formulary. For Invega Sustenna, which is used to treat schizophrenia and schizoaffective disorder, Medicare generally covers it when prescribed by a healthcare provider for an FDA-approved indication [1].
What if my Medicare plan doesn't cover Invega Sustenna?
If a specific Medicare Part D plan does not cover Invega Sustenna, patients may have a few options. They can inquire about an exception or formulary appeal if they believe the drug is medically necessary and no suitable alternatives are available. Alternatively, they might consider switching to a different Medicare Part D plan during the annual enrollment period that does include Invega Sustenna on its formulary. The manufacturer of Invega Sustenna may also offer patient assistance programs that can help offset costs for eligible individuals [2].
Are there other long-acting injectable antipsychotics Medicare covers?
Yes, Medicare Part D plans often cover other long-acting injectable antipsychotics besides Invega Sustenna. The availability and formulary placement of these medications can vary by plan. Examples of other long-acting injectables that may be covered include those containing active ingredients like aripiprazole, haloperidol decanoate, or risperidone consta [1].
What is the difference between Invega Sustenna and Invega Trinza?
Invega Sustenna and Invega Trinza are both long-acting injectable antipsychotic medications containing paliperidone palmitate, but they differ in their dosing frequency. Invega Sustenna is typically administered once a month, whereas Invega Trinza is designed for less frequent administration, usually once every three months, after an initial loading dose period [3].
Who makes Invega Sustenna and what are its patents?
Invega Sustenna is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [3]. Information regarding patents for Invega Sustenna and its potential generic or biosimilar competition can be found on specialized drug patent databases [4].
Sources
[1] Medicare.gov
[2] Invega Sustenna Official Website
[3] Janssen Pharmaceuticals
[4] DrugPatentWatch.com